Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Ryan

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
JACC. Advances|April 3, 2026
Obesity Pharmacotherapy: An Urgent Need for Progressing Science, Access, and Equity-JACC: Advances Expert PanelPishoy Gouda, Nadine Allyn, Ruth Belin, et al.
Nature Medicine|June 24, 2026
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Diabetes Care|June 22, 2024
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECTIldiko Lingvay, John Deanfield, Steven E Kahn, et al.
Nature Medicine|June 5, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Journal of the American College of Cardiology|September 1, 2024
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT TrialBenjamin M Scirica, A Michael Lincoff, Ildiko Lingvay, et al.
Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 13, 2026
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025Stefan D Anker, Linong Ji, Tammy Kindel, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
JACC. Advances|April 3, 2026
Obesity Pharmacotherapy: An Urgent Need for Progressing Science, Access, and Equity-JACC: Advances Expert PanelPishoy Gouda, Nadine Allyn, Ruth Belin, et al.
Nature Medicine|June 24, 2026
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Diabetes Care|June 22, 2024
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECTIldiko Lingvay, John Deanfield, Steven E Kahn, et al.
Nature Medicine|June 5, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Journal of the American College of Cardiology|September 1, 2024
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT TrialBenjamin M Scirica, A Michael Lincoff, Ildiko Lingvay, et al.
Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 13, 2026
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025Stefan D Anker, Linong Ji, Tammy Kindel, et al.
Pageof 4